Legacy Reserves LP (LGCY) Reaches $2.00 Formed H&S; Clough Capital Partners LP Upped Biomarin Pharmaceutical (BMRN) Stake By $2.75 Million

May 31, 2017 - By marketbeat

Clough Capital Partners LP increased Biomarin Pharmaceutical Inc (BMRN) stake by 52.19% reported in 2016Q4 SEC filing. Clough Capital Partners LP acquired 33,509 shares as Biomarin Pharmaceutical Inc (BMRN)’s stock declined 0.71%. The Clough Capital Partners LP holds 97,709 shares with $8.09M value, up from 64,200 last quarter. Biomarin Pharmaceutical Inc now has $15.45 billion valuation. The stock decreased 0.13% or $0.11 during the last trading session, reaching $87.89. About shares traded. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) has risen 5.29% since May 31, 2016 and is uptrending. It has underperformed by 11.41% the S&P500.

Legacy Reserves LP (LGCY) formed H&S with $1.88 target or 6.00% below today’s $2.00 share price. Legacy Reserves LP (LGCY) has $142.43 million valuation. The stock decreased 0.99% or $0.02 on May 30, reaching $2. About shares traded. Legacy Reserves LP (NASDAQ:LGCY) has declined 15.20% since May 31, 2016 and is downtrending. It has underperformed by 31.90% the S&P500.

Among 20 analysts covering BioMarin Pharmaceutical (NASDAQ:BMRN), 13 have Buy rating, 0 Sell and 7 Hold. Therefore 65% are positive. BioMarin Pharmaceutical had 42 analyst reports since August 5, 2015 according to SRatingsIntel. Wedbush maintained the stock with “Hold” rating in Wednesday, August 5 report. The rating was initiated by Goldman Sachs with “Buy” on Wednesday, November 18. The rating was maintained by Oppenheimer on Wednesday, November 25 with “Perform”. The rating was upgraded by Stifel Nicolaus on Tuesday, February 16 to “Buy”. Raymond James initiated the stock with “Outperform” rating in Tuesday, September 1 report. Deutsche Bank maintained the stock with “Buy” rating in Wednesday, August 5 report. Wedbush maintained BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) on Tuesday, January 19 with “Neutral” rating. Wedbush maintained BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) on Monday, October 5 with “Neutral” rating. As per Friday, August 5, the company rating was maintained by Barclays Capital. Wedbush maintained it with “Neutral” rating and $131 target in Tuesday, August 25 report.

Since January 6, 2017, it had 0 insider purchases, and 22 selling transactions for $13.92 million activity. BIENAIME JEAN JACQUES sold $960,850 worth of stock. Shares for $29,215 were sold by Ajer Jeffrey Robert on Tuesday, May 2. The insider Davis George Eric sold $205,806. The insider SPIEGELMAN DANIEL K sold 35,000 shares worth $3.29M. $687,334 worth of stock was sold by Mueller Brian on Friday, April 28. 7,500 BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) shares with value of $712,500 were sold by LAWLIS V BRYAN.

Investors sentiment decreased to 1.04 in Q4 2016. Its down 0.62, from 1.66 in 2016Q3. It dropped, as 50 investors sold BMRN shares while 129 reduced holdings. 50 funds opened positions while 136 raised stakes. 165.79 million shares or 0.67% more from 164.68 million shares in 2016Q3 were reported. 4,290 were reported by Greenwood Cap Limited Co. Profund Advisors Limited Com stated it has 0.32% of its portfolio in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). Clough Prtn L P, Massachusetts-based fund reported 97,709 shares. Fmr Limited Com owns 8.89 million shares for 0.1% of their portfolio. Blackrock Advisors Ltd holds 384,886 shares or 0.03% of its portfolio. Glenmede Tru Com Na, a Pennsylvania-based fund reported 16,419 shares. Swiss Bancshares holds 466,100 shares. Quantum Cap Management invested in 2.09% or 93,788 shares. Mitsubishi Ufj Bk has invested 0.06% in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). Qvt Fincl Lp stated it has 63,179 shares or 0.16% of all its holdings. Loring Wolcott & Coolidge Fiduciary Llp Ma accumulated 0% or 1,100 shares. Gilder Gagnon Howe & Ltd Liability holds 0.4% in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) or 243,836 shares. Aviva Public Ltd Liability Corp invested in 0.05% or 109,382 shares. Jane Street Gru Ltd Llc owns 27,768 shares or 0.01% of their US portfolio. Allstate Corp stated it has 0.2% in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN).

Clough Capital Partners LP decreased Parsley Energy Inc (NYSE:PE) stake by 629,433 shares to 161,167 valued at $5.68 million in 2016Q4. It also reduced Prestige Brands Hldgs Inc (NYSE:PBH) stake by 19,000 shares and now owns 43,300 shares. Two Hbrs Invt Corp (NYSE:TWO) was reduced too.

Investors sentiment increased to 0.63 in Q4 2016. Its up 0.20, from 0.43 in 2016Q3. It improved, as 9 investors sold Legacy Reserves LP shares while 15 reduced holdings. 8 funds opened positions while 7 raised stakes. 14.63 million shares or 12.10% more from 13.05 million shares in 2016Q3 were reported. First Dallas stated it has 0.02% of its portfolio in Legacy Reserves LP (NASDAQ:LGCY). Fifth Third Commercial Bank reported 600 shares or 0% of all its holdings. National Bank Of America De invested in 0% or 38,698 shares. 100,000 were accumulated by Rr Advsr Ltd Liability. Columbia Asset Mngmt has invested 0.01% in Legacy Reserves LP (NASDAQ:LGCY). Hodges Cap Mgmt Incorporated invested in 21,580 shares or 0% of the stock. Cetera Advsr Limited Liability Company holds 0% or 20,000 shares in its portfolio. Susquehanna Group Inc Incorporated Llp holds 0% or 69,534 shares in its portfolio. Stifel holds 25,536 shares or 0% of its portfolio. Us Financial Bank De owns 2,400 shares for 0% of their portfolio. Credit Suisse Ag reported 0% stake. Adirondack invested 0% of its portfolio in Legacy Reserves LP (NASDAQ:LGCY). Goldman Sachs Inc, New York-based fund reported 10,806 shares. Prescott Gp Mngmt Ltd Liability holds 0.22% or 487,566 shares in its portfolio. Commonwealth Financial Svcs Ltd Liability holds 621 shares.